BeStock  
Stocks › Biotechnology › AVTX

Avalo Therapeutics AVTX

US equityMarket cap rank #3681Biotechnology
$6.76 +$0.01 (+0.15%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $6.76 0.00%
Open$6.65
Prev close$6.75
Day range$6.61 – $7.03
Volume1.18M
Market cap$390.88M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$23.40M-21.9% YoY
Net profit-$18.95M+38.1% YoY
Diluted EPS-$0.34+84.5% YoY
Free cash flow-$11.54M+29.5% YoY
Operating cash flow-$11.54M

Revenue, last 8 quarters

$192.0KDec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$59.0KDec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-35.3MDec '24$-13.1MMar '25$-20.8MJun '25$-30.6MSep '25$-13.7MDec '25$-19.6MMar '26$-36.4MJun '26$-18.9MSep '26

Diluted EPS by quarter

-3.36Dec '24-1.25Mar '25-1.92Jun '25-2.19Sep '25-0.37Dec '25-0.98Mar '26-0.83Jun '26-0.34Sep '26

Free cash flow by quarter

$-15.0MDec '24$-9.5MMar '25$-11.4MJun '25$-16.4MSep '25$-14.2MDec '25$-17.7MMar '26$-20.0MJun '26$-11.5MSep '26

Annual revenue

$6.7MFY20$5.4MFY21$18.1MFY22$1.9MFY23$441.0KFY24$59.0KFY25

Profitability & balance sheet

Operating margin-161,962.7%
Net margin-150,259.3%
Return on equity-33.6%
Return on assets-29.2%
Return on invested capital-33.5%
Current ratio16.63
Liabilities / assets9.3%
Cash & investments$392.97M
Total debt$0.00
Net cash (debt)$392.97M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $59,000.00 $59,000.00
Operating Expense $23.40M $31.52M $20.90M $72.98M $19.80M
Selling and Admin Expenses $8.35M $8.10M $6.85M $22.90M $6.53M
-Selling & Marketing Expense $123,000.00 $126,000.00 $209,000.00 $470,000.00 $381,000.00
-General & Admin Expense $8.23M $7.97M $6.65M $22.43M $6.15M
Research & Development $15.05M $23.42M $14.05M $50.08M $13.27M
Operating Profit -$23.40M -$31.52M -$20.90M -$72.93M -$19.74M
Net Non-Operating Interest Income (Expense) $4.25M $2.76M $803,000.00 $4.35M $992,000.00
Non-Operating Interest Income $4.25M $2.76M $803,000.00 – –
Other Income (Expense) $210,000.00 -$7.58M $480,000.00 -$9.52M $5.16M
Gain on Sale of Security $210,000.00 -$1.01M $480,000.00 -$9.52M $5.16M
Special Income (Charges) $0.00 -$6.57M – $0.00 $0.00
-Less:Restructuring and Mergern & Acquisition $0.00 $6.57M – $0.00 $0.00
Pretax Profit -$18.94M -$36.34M -$19.62M -$78.09M -$13.59M
Tax $7,000.00 $18,000.00 $12,000.00 $165,000.00 $130,000.00
Net Profit -$18.95M -$36.36M -$19.63M -$78.26M -$13.72M
Profit from Continuing Operations -$18.95M -$36.36M -$19.63M -$78.26M -$13.72M
Net Income to Parent Company -$18.95M -$36.36M -$19.63M -$78.26M -$13.72M
Net Income to Common Stockholders -$18.95M -$36.36M -$19.63M -$78.26M -$13.72M
Basic EPS -$0.34 -$0.83 -$0.98 -$5.84 -$0.37
Diluted EPS -$0.34 -$0.83 -$0.98 -$5.84 -$0.37
Total Revenue as Reported – – – $59,000.00 $59,000.00
Cost of Revenue – – – $0.00 $0.00
Gross Profit – – – $59,000.00 $59,000.00
Total Other Finance Costs – – – -$4.35M –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $481.43M $490.78M $99.89M $116.46M $116.46M
Total Current Assets $400.74M $407.93M $88.83M $105.29M $105.29M
Cash and Cash Equivalents & Short-Term Investments $392.97M $400.28M $81.99M $98.34M $98.34M
-Cash and Cash Equivalents $64.99M $85.38M $24.99M $15.86M $15.86M
-Short Term Investments $327.98M $314.89M $57.01M $82.48M $82.48M
Restricted Cash $211,000.00 $49,000.00 $147,000.00 $37,000.00 $37,000.00
Other Current Assets $7.56M $7.61M $6.69M $6.91M $6.91M
Total Non-Current Assets $80.70M $82.85M $11.06M $11.17M $11.17M
Net PPE $198,000.00 $288,000.00 $375,000.00 $460,000.00 $460,000.00
Investments and Advances $69.81M $71.88M – – –
Goodwill and Other Intangible Assets $10.50M $10.50M $10.50M $10.50M $10.50M
-Goodwill $10.50M $10.50M $10.50M $10.50M $10.50M
Other Non-Current Assets $183,000.00 $183,000.00 $183,000.00 $210,000.00 $210,000.00
Total Liabilities $44.88M $42.12M $31.57M $33.41M $33.41M
Total Current Liabilities $24.09M $21.13M $11.60M $12.94M $12.94M
Payables $2.46M $3.35M $683,000.00 $464,000.00 $464,000.00
-Accounts Payable $2.46M $3.35M $356,000.00 $137,000.00 $137,000.00
Current Accrued Expenses $17.13M $14.74M $8.84M $7.95M $7.95M
Short-Term Debt and Capital Lease Obligation $153,000.00 $242,000.00 $328,000.00 $392,000.00 $392,000.00
-Current Capital Lease Obligation $153,000.00 $242,000.00 $328,000.00 $392,000.00 $392,000.00
Total Non-Current Liabilities $20.79M $20.99M $19.97M $20.47M $20.47M
Long Term Debt and Capital Lease Obligation $0.00 $0.00 $0.00 – –
-Long Term Capital Lease Obligation $0.00 $0.00 $0.00 – –
Derivative Product Liabilities $18.32M $18.53M $17.52M $18.00M $18.00M
Non-Current Deferred Liabilities $470,000.00 $463,000.00 $446,000.00 $434,000.00 $434,000.00
Convertible preferred securities $0.00 $0.00 $0.00 $0.00 $0.00
Other Non-Current Liabilities $2.00M $2.00M $2.00M $2.04M $2.04M
Total Equity $436.55M $448.66M $68.32M $83.05M $83.05M
Stockholders' Equity $436.55M $448.66M $68.32M $83.05M $83.05M
Capital Stock $54,000.00 $53,000.00 $25,000.00 $18,000.00 $18,000.00
-Common Stock $54,000.00 $53,000.00 $25,000.00 $18,000.00 $18,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $961.46M $953.70M $536.45M $531.49M $531.49M
Retained Earnings -$523.46M -$504.51M -$468.15M -$448.52M -$448.52M
Gains/Losses Not Affecting Retained Earnings -$1.51M -$583,000.00 -$6,000.00 $68,000.00 $68,000.00
-Other Payable – – $327,000.00 $327,000.00 $327,000.00
-Gross PPE – – – $713,000.00 $713,000.00
-Accumulated Depreciation – – – -$253,000.00 -$253,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$11.54M -$19.99M -$17.69M -$51.46M -$14.25M
Net cash flow from continuing operations -$11.54M -$19.99M -$17.69M -$51.46M -$14.25M
Net Income from Continuing Operations -$18.95M -$36.36M -$19.63M -$78.26M -$13.72M
Gain/Loss from Continuing Operations -$210,000.00 $1.01M -$480,000.00 $9.52M -$5.16M
Depreciation & Depletion & Amortization $18,000.00 $17,000.00 $17,000.00 $344,000.00 $16,000.00
Deferred Tax $7,000.00 $17,000.00 $12,000.00 $165,000.00 $131,000.00
Other Non-Cash Items $0.00 $1.87M -$106,000.00 -$690,000.00 –
Change in Working Capital $3.09M $8.68M -$1.08M $3.84M $176,000.00
-Change in Prepaid Assets $49,000.00 -$922,000.00 $228,000.00 -$2.59M -$4.77M
-Change in Payables and Accrued Expense $3.05M $9.62M -$1.28M $6.52M $5.01M
-Change in Other Current Liabilities -$17,000.00 -$16,000.00 -$31,000.00 -$87,000.00 -$63,000.00
Net cash flow from investing -$11.23M -$329.93M $25.51M -$81.72M $2.40M
Net Cash Flow from Continuing Investing Activities -$11.23M -$329.93M $25.51M -$81.72M $2.40M
Net Investment Purchase and Sale -$11.23M -$329.93M $25.51M -$81.72M $2.40M
Financing Cash Flow $2.54M $410.21M $1.40M $14.59M $687,000.00
Net Cash Flow from Continuing Financing Activities $2.54M $410.21M $1.40M $14.59M $687,000.00
Net Common Stock Issuance $0.00 – – $14.76M $392,000.00
Proceeds from Stock Option Exercised $2.54M $5.30M $2.18M $797,000.00 $757,000.00
Net Other Financing Charges $0.00 -$26.40M -$779,000.00 -$972,000.00 -$462,000.00
Ending Cash Balance $65.38M $85.61M $25.32M $16.11M $16.11M
Net Change in Cash -$20.23M $60.30M $9.21M -$118.59M -$11.16M
Beginning Cash Balance $85.61M $25.32M $16.11M $134.70M $27.26M
Free Cash Flow -$11.54M -$19.99M -$17.69M -$51.46M -$14.25M
-Change in Receivables – – – $0.00 –
Net Business Purchase and Sale – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on AVTX.

Sign in to join the discussion.

Scroll to Top